* Reports positive preclinical data in heart treatment
* Study shows treatment does not cause arrhythmias in
* Shares up 3 pct
May 13 Geron Corp (GERN.O) said data from a
preclinical study showed its experimental stem-cell product for
the treatment of chronic heart injury did not cause any
abnormal electrical activity after it was transplanted in the
site of the injury.
The product, GRNCM1, was tested in guinea pigs with chronic
cardiac injury, to assess whether transplantation increases the
incidence of cardiac arrhythmia, a safety concern for cardiac
Arrhythmia is an abnormality of the heart rhythm, which can
cause the heart to pump less efficiently.
The company said the study showed that there was no
significant difference in the incidence of either spontaneous
or induced arrhythmias between those receiving GRNCM1 and a
Geron is currently conducting studies in a swine model of
heart attack to further test the preclinical safety and
efficacy of the product.
Shares of the company were trading up about 1 percent at
$5.79 Thursday afternoon on Nasdaq. They touched a high of
$5.91 earlier in the day.
(Reporting by Krishnakali Sengupta in Bangalore; Editing by